Section Arrow
Quote
XTLB.NASDAQ
- XTL Biopharmaceuticals Ltd
(Financial Status)
Quotes are at least 15-min delayed:2026/01/06 20:17 EST
Regular Hours
Last
 0.688
+0.054 (+8.52%)
Day High 
0.69 
Prev. Close
0.634 
1-M High
3.6 
Volume 
30.95K 
Bid
0.63
Ask
0.6663
Day Low
0.638 
Open
0.6393 
1-M Low
0.5301 
Market Cap 
5.59M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.43 
20-SMA 2.38 
50-SMA 3.27 
52-W High 10.2796 
52-W Low 0.5301 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.90/-0.71
Enterprise Value
5.59M
Balance Sheet
Book Value Per Share
-0.01
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
451.00K
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
CYCNCyclerion Therapeutics1.95+0.57+41.30%-- 
ALMSAlumis Inc.16.23+7.92+95.31%0.33PE
MREOMereo BioPharma Group plc0.379-0.1016-21.14%-- 
SLSSELLAS Life Sciences Group4.1-0.9-18.00%-- 
RXRXRecursion Pharmaceuticals4.55+0.18+4.12%-- 
Industry overview quotes are at least 15 minutes delayed
Business Description
XTL Biopharmaceuticals Ltd is engaged in the development of therapeutics for the treatment of unmet medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE) and Sjogren's syndrome. hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.